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Abstract Reported here is a case of a patient with pul-
monary arterial hypertension related to HIV (PAHRH) in
which lipodystrophy necessitated interruption of highly ac-
tive antiretroviral therapy (HAART) and long-term survival
was the outcome. Although previous studies have suggested
antiretroviral therapy may benefit patients with this rare
complication of HIV infection, no worsening of PAHRH
was observed when HAART was interrupted. Clinical
and echocardiographic parameters remained stable during
7 months of follow up. In cases in which HAART is as-
sociated with relevant toxicity, interruption of HAART in
patients with PAHRH can be considered, but should be
used only if no alternatives are available. Close follow-up
is warranted.
Introduction
HIV-infected individuals have a 0.5% incidence of pul-
monary arterial hypertension, compared to 0.02% in the
non-HIV-infected population [1, 2]. Prognosis is poor, with
a median survival period of 6 months, and treatment op-
tions are limited. In prospective studies of patients with
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PAHRH, the introduction of highly active antiretroviral
therapy (HAART) has been found to improve right-sided
heart pressure and mortality [3], and resolution of PAHRH
has been described in some patients. It should be men-
tioned, however, that patients in these studies were often
treated with both HAART and PAHRH treatment, mak-
ing the specific contribution of each of these interventions
difficult to differentiate. Furthermore, some studies have
found an increased incidence of PAHRH in patients receiv-
ing HAART (reviewed in [4]). In the present report, we
describe a patient with an atypical course of PAHRH in
whom lipodystrophy necessitated interruption of HAART.
During cessation of HAART, PAHRH remained stable, de-
spite a rise in the patient’s HIV viral load and a fall in his
CD4+ cell count.
Case report
A 34-year-old male with a history of intravenous drug use
was diagnosed with PAHRH 7 years after he had tested
positive for HIV. The diagnosis of PAHRH was established
after echocardiography to evaluate a rapidly progressing
episode of dyspnea revealed a right ventricular systolic
pressure of 59 mmHg over right atrial pressure (RV/RA
pressure gradient); the diagnosis was confirmed by invasive
assessment. Secondary causes were excluded. The evolu-
tion and treatment of PAHRH and HIV in this case are
shown in Table 1.
PAHRH stabilized under a therapy consisting of
isosorbidinitrate, phenprocoumon and digoxin. At the
time of PAHRH diagnosis, antiretroviral monotherapy
with zidovudine (AZT) was started, with the subsequent
addition of lamivudine (3TC). Three years later HAART
was started with the addition of indinavir. Five years after
PAHRH was diagnosed, clinical and echocardiographic
signs of progression were noted, and an ACE inhibitor
was added to the antibiotic regimen. A trial with the
prostacyclin analogue iloprost (ilomedin; Schering, Baar,
Switzerland) (inhalation, 3–5 times a day) led to marked
clinical improvement but had to be stopped because it was
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Table 1 Diagnostic procedures, therapy, CD4+ cell count and viral load over time in a HIV-infected patient with pulmonary arterial
hypertension
Date
(mm/yy)/
diagnosis
Diagnostic tests Clinical
presentationd
Therapy Laboratory results
Echoa/PAKb 6 min walking
test/Borg scalec
PAH HIV CD4
(cells/ul)
Viral load
(copies/ml)
1987 HIV
01/94 PAH E: 59/32 II phenprocoumon, digoxin
(0.375 mg)
AZT 860 nd
03/94 PAK(1) II unchanged AZT
09/95 E: 65/25 same + isosorbidinitrate
(40 mg)
AZT, 3TC 680 nd
03/97 unchanged 3TC, d4T, IDV 650 nd
03/99 E: 75/32; right
ventricle enlarged
III, edema
lower
extremities
+ lisinopril/
hydrochlorothiazide
3TC, d4T,
efavirenz
1769 n
01/00 PAK (2) 470 m/2 +ilomedin (5×/d p.i.
10 µg)
3TC, d4T,
nevirapine
nd n
02/00 556 m/2 unchanged unchanged nd n
05/00 633 m/2 I-II unchanged unchanged 1807 n
07/00 670 m/2 I ilomedin stop unchanged nd n
01/01 E: not measurable/20 II phenprocoumon, digoxin,
lisinopril/
hydrochlorothiazide
unchanged nd n
01/02 E: not measurable/20 II unchanged unchanged 1231 n
11/02 550 m/4 II unchanged unchanged nd n
12/02 E: not measurable/24 II unchanged HAART stop 1828 n
01/03 570 m/2 II unchanged unchanged 1215 2235000
03/03 500 m/2 II unchanged unchanged 794 154500
06/03 600 m/2 II unchanged unchanged 692 351000
07/03 E: not measurable/24 II unchanged tenofovir,
nevirapine ddI
nd nd
08/03 II unchanged unchanged 757 1080
10/03 unchanged unchanged 826 106
01/04 E: not measurable/21 1050 m/1 unchanged unchanged 1097 n
E, echocardiography; PAK, pulmonary artery catheter; PAH, pulmonary arterial hypertension; HIV, human immunodeficiency virus; AZT,
zidovudine; 3TC, lamivudine; d4T, stavudine; IDV, indinavir; HAART, highly active antiretroviral therapy; ddI, didanosine; VL, viral load;
nd, not done; n, not detectable
aFirst number = right ventricular systolic pressure in mmHg over right atrial pressure in mmHg; Second number = right ventricular diastolic
pressure in mmHg over right atrial pressure in mmHg
b(1) Values 3/94: cardiac index 2.6 l/min, pulmonary resistance 625 dyne (no decrease of pulmonary resistance under infusion of prostin
450 ug/h), median pulmonary arterial pressure 46 mmHg, wedge pressure 6 mmHg
(2) Values 1/00: before ilomedin: cardiac index 2.0 l/min, pulmonary resistance 1126 dyne, median pulmonary arterial pressure 61 mmHg;
after ilomedin: cardiac index 2.8 l/min, pulmonary resistance 756 dyne, median pulmonary arterial pressure 56 mmHg
cThe Borg scale rates shortness of breath in a range from 0 to 10 whereby 0 indicates no shortness of breath at all while 10 indicates very,
very severe shortness of breath
dClinical presentation was coded in accordance with the guidelines of the New York Heart Association whereby I = symptoms of heart
failure only at levels that would limit normal individuals, II = symptoms of heart failure with ordinary exertion, III = symptoms of heart
failure on less than ordinary exertion, and IV = symptoms of heart failure at rest
causing persisting headaches. Phenprocoumon, digoxin,
lisinopril/hydrochlorothiazide were continued, and
PAHRH was noted to have stabilized clinically; this was
confirmed by echocardiography.
At the time PAHRH first worsened (3/99), a significant
exacerbation of the patient’s lipodystrophy was noted
under therapy with 3TC, stavudine (d4T), and indinavir.
Indinavir was replaced by efavirenz and later by nevirapine.
Lipodystrophy and, particularly, the buffalo hump pro-
gressed further. The patient became severely handicapped,
not being able to hold his head upright. Surgical therapy
of the buffalo hump was considered but was felt to be too
risky considering the PAHRH. Further testing revealed the
patient’s CD4+ cell count had risen to 1828 cells/µl (54%)
and his viral load was persistently non-detectable. On
echocardiography, the systolic pulmonary arterial pressure
gradient was no longer detectable, and diastolic pressure
remained slightly elevated. Due to these excellent values
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and the progressing lipodystrophy, HAART was stopped
with the consent of the patient. One month later the patient’s
viral load had risen to >2×106 copies/ml and the CD4+
cell count had fallen from 1882 to 1215 cells/µl. Dyspnea
remained stable as did the echocardiography results.
The patient asked to resume HAART 7 months after it was
stopped despite the fact that PAHRH had almost completely
regressed and lipodystrophy had not worsened. HAART
was restarted with tenofovir, nevirapine and didanosine.
The viral load again became fully suppressed and the CD4+
cell count rose to 826 cells/µl. Eighteen months following
re-initiation of HAART, PAHRH had not recurred, but the
lipodystrophy still remained a problem.
Discussion
The pathogenesis of PAHRH is largely unknown, but HIV-
induced cytokines, endothelin-1, human herpes virus 8, or
HIV-mediated autoimmune disease, among other factors,
may play a role [3–6]. Prognosis of PAHRH is bad, with a
median survival of 6 months after diagnosis. As with pri-
mary pulmonary hypertension, treatment options are lim-
ited. Newer agents such as bosentan and sildenafil [7–9]
are under investigation. Given the potential role of HIV in
the pathogenesis of PAHRH, the role of HAART has been
examined. In a retrospective study on the role of anti-HIV
treatment in PAHRH, HAART was found to be beneficial in
terms of hemodynamic parameters and survival [10]. How-
ever, HAART alone did not always lead to an improvement
of PAHRH, and in some studies it was associated with a
higher incidence of PAHRH [4].
Several aspects of the case described here are noteworthy.
In this patient PAHRH remained stable for over 5 years
after its initial diagnosis and it regressed almost completely
during the further course. Although antiretroviral therapy
(initially AZT monotherapy, then AZT and 3TC) had been
started at the time PAHRH was diagnosed, its impact is
difficult to judge, since no viral load measurements are
available from this time. While it is unlikely that the
initial treatment resulted in complete viral suppression,
it might have prevented a relevant loss of CD4+ cells,
since all CD4+ cell counts were above 200/ul. The length
of the stable phase in this patient strongly contrasts with
the short survival period previously reported for patients
with PAHRH but without anti-HIV treatment. Intermittent
deterioration of PAHRH in this patient occurred despite
complete suppression of viral replication (documented for
the first time 4 years after PAHRH diagnosis) and CD4+
cell counts >1000 cells/µl. Possible triggers for the sudden
deterioration are not known. Inhalation therapy with
ilomedin improved cardiac performance, but had to be
stopped due to uncontrollable headaches. Due to the pro-
gression of severe lipodystrophy, HAART was interrupted;
however, this decision was made reluctantly given the
relatively long survival of the patient despite PAHRH and
the potential role HAART might have played. Fortunately,
no progression of PAHRH was noted after HAART was in-
terrupted. It should be emphasized that PAHRH treatment
was continued during the interruption of HAART, which
at least questions the impact of HAART on the PAHRH.
Despite the favorable course reported here, close follow-
up of patients with PAHRH is necessary to detect early
signs of deterioration if HAART interruption is considered.
Interruption of HAART should be reserved for cases in
which no alternatives are available.
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